Doctor Sukrut Shah

Rahway (United States of America)

Follow

Contributor content

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

Presentation

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

ESC 365 is supported by

novartis

Explore sponsored resources